Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon‐γ

European Journal of Immunology - Tập 26 Số 10 - Trang 2393-2398 - 1996
Hubertine Heremans1, Chris Dillen2, Marleen Groenen2, Erik Martens2, Alfons Billiau2
1Rega Institute, University of Leuven, Laboratory of Immunobiology, Minderbroeders‐straat 10, B‐3000 Leuven, Belgium, Fax: +32‐16‐33‐73‐40
2Laboratory of Immunobiology, Rega Institute, University of Leuven Medical School, Leuven, Belgium

Tóm tắt

AbstractExperimental autoimmune encephalomyelitis (EAE) is a T cell‐mediated inflammatory and demyelinating disorder of the central nervous system. Depending on the experimental conditions, it takes an acute monophasic or a chronic relapsing‐remitting course. We have previously reported that the incidence and severity of acute EAE in mice are reduced by administration of interferon (IFN)‐γ and augmented by treatment with neutralizing antibodies against IFN‐γ. Here, we investigated the role of IFN‐γ in chronic relapsing models of EAE (CREAE) in SJL/J and Biozzi ABH mice. Spontaneous relapses in Biozzi mice as well as induced relapses in SJL/J mice were facilitated by administration of neutralizing monoclonal antibody (mAb) against IFN‐γ in the disease‐free interval. The enhancing effect of anti‐IFN‐γ mAb given before and during the primary attack did not carry over to the relapses. However, early administration of IFN‐γ in Biozzi mice, which developed spontaneous relapses in a high proportion, provided partial protection not only against the first attack, but also against subsequent relapses. Administration of exogenous IFN‐γ during the remission phase provided some protection against subsequent relapses. These results indicate that in both types of relapses, IFN‐γ is produced and does provide a certain degree of protection against disease progression.

Từ khóa


Tài liệu tham khảo

10.1111/j.1749-6632.1984.tb14774.x

10.1146/annurev.iy.10.040192.001101

10.1146/annurev.iy.08.040190.003051

Brown A. M., 1981, Lab. Invest., 45, 278

10.1038/309356a0

10.1016/0165-5728(90)90019-J

Cross A. H., 1987, Lab. Invest., 57, 499

10.1096/fasebj.5.2.1825981

Mc Donald A. H., 1988, J. Immunol., 140, 1132, 10.4049/jimmunol.140.4.1132

10.1016/0165-5728(91)90022-Y

10.4049/jimmunol.149.7.2496

10.1084/jem.176.5.1355

10.1016/0165-5728(94)90174-0

10.1146/annurev.iy.11.040193.003035

Billiau A., 1988, J. Immunol., 140, 1506, 10.4049/jimmunol.140.5.1506

10.1016/0165-5728(92)90042-J

10.3109/08916939309014645

10.1016/S0140-6736(87)92863-7

Dijkmans R., 1987, J. Biol. Chem., 262, 2528, 10.1016/S0021-9258(18)61536-4

10.1099/0022-1317-67-6-1059

Heremans H., 1987, J. Immunol., 138, 4175, 10.4049/jimmunol.138.12.4175

10.1016/0959-4388(93)90153-P

10.1159/000236650

Issekutz T. B., 1990, J. Immunol., 144, 2140, 10.4049/jimmunol.144.6.2140

10.1016/0165-5728(93)90071-6

Gosselin D., 1955, J. Leukocyte Biol., 57, 122, 10.1002/jlb.57.1.122

10.1172/JCI117973

10.1172/JCI117282

10.1016/0165-5728(94)00192-Q

10.1111/j.1365-2249.1996.tb08304.x

10.1073/pnas.89.2.574

10.1016/0167-5699(94)90151-1

10.1084/jem.181.1.381

Thông tin
Thông tin xuất bản

European Journal of Immunology

Tập 26 Số 10

2393-2398

Thông tin tác giả